June 13, 2019
Today the immuno-oncology (I-O) represents a revolution in the ﬁeld of oncology. The checkpoints inhibitors (anti-CTLA4, anti-PD-1, etc.), are able to kill cancer cells indirectly, through the interaction with the immune system cells.
The characteristics of adaptability and memory of the immune-system make it able to reach longterm survival (more than 10 years). For this reason, I-O became the fourth pillars in the treatment of cancer together surgery, radiotherapy, and chemotherapy.
After the excellent results reached in different type of cancers, I-O is exploring a wide range of new molecules and possible combinations or sequencing, in order to increase the number of patients with a long-term beneﬁt.
The intent of this course, with contributions from Società Campana di Immunoncologia (SCITO) is to offer a general educational overview about the topics described. In addition, thanks to the contribution of Karolinska Institute of Stockholm, this course goes beyond national borders taking on an international aspect.